Basal cell carcinoma - Basozelulen Kartzinoma
☆ Alemaniako Stiftung Warentest-en 2022ko emaitzetan, ModelDerm-ekin kontsumitzaileen gogobetetasuna apur bat txikiagoa izan zen ordaindutako telemedikuntzako kontsultekin baino.
Adineko pertsonen sudurreko larruazalean eragiten duten ultzeratutako lesioak sarritan Basozelulen Kartzinoma (Basal cell carcinoma) gisa diagnostikatzen dira. Sudurra azaleko minbizi mota honen ohiko agerraldia da.
Basozelulen Kartzinoma (Basal cell carcinoma) ertz irregularrak eta ultzerak ager daitezke.
Basozelulen Kartzinoma (Basal cell carcinoma) garatxoarekin nahas daiteke.
relevance score : -100.0%
ReferencesBasal cell carcinoma (BCC) azaleko minbizi mota ohikoena da. Eguzki‑argia jasotzea da kausa nagusia. BCC kasu ia guztiek analisi molekularrean Hedgehog‑en seinaleztapena erakusten dute. Tratamendu desberdinak eskuragarri daude eta hauek errepikatzeko arriskuaren, ehunen kontserbazioaren garrantziaren, pazientearen hobespenaren eta gaixotasunaren neurriaren arabera hautatzen dira.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinoma (larruazaleko minbizi mota) ohikoena da 50 urtetik gorako larruazal zuriko helduen artean. Haien kopurua gero eta handiagoa ari da mundu osoan, batez ere eguzki-argiaren eraginpean egoteko. Zenbait baldintza genetikoek adin txikiagoan minbizi hauek garatzeko joera izan dezakete. Basal cell carcinoma‑ren larritasuna aldatu egiten da: erraz tratatu daitezkeen azaleko edo nodular lesioetatik hasi eta mediku talde espezializatuetan eztabaidatu behar diren zabalagoetaraino. Pronostikoa minbizia itzultzeko probabilitatearen edo inguruko ehunak kaltetzeko duen gaitasunaren araberakoa da. Kirurgia tratamendu estandarra da kasu gehienetarako, kentzea zehatza eta errepikatzeko aukera baxuak bermatuz. Metodo gutxiagoko inbaditzaileek modu eraginkorrean trata ditzakete azaleko lesioak.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
BCCren tratamendu nagusia kirurgia da. Arrisku handiko edo errepikakorra den BCCrako, bereziki eremu kritikoetan, mikrografikoki kontrolatutako kirurgia gomendatzen da. Arrisku baxuko azaleko BCC duten pazienteek tratamendu topikoak edo metodo suntsitzaileak kontuan izan ditzakete. Terapia fotodinamikoak ondo funtzionatzen du azaleko eta arrisku baxuko BCC nodularretarako. BCC lokal aurreratu edo metastatikorako, Hedgehog inhibitzaileak (vismodegib edo sonidegib) gomendatzen dira. Hedgehog inhibitzaileekiko gaixotasunaren progresioa edo intolerantzia badago, anti‑PD1 antibody (cemiplimab) immunoterapia kontuan hartu daiteke. Erradioterapia aukera ona da ebakuntza ezin duten pazienteentzat, batez ere adineko pazienteentzat. Elektrokimioterapia kontuan hartu daiteke kirurgia edo erradioterapia aukera bat ez badago.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
Arrisku-faktoreak argi ultramorearen esposizioa, erradioterapia, artsenikoarekiko epe luzeko esposizioa eta immunitate-sistemaren funtzio eskasa (adibidez, organoen transplantea) dira. Haurtzaroan UV argiaren esposizioa bereziki kaltegarria da.
Biopsiaren bidez diagnostikatu ondoren, tratamendua normalean kentze kirurgikoa izaten da. Minbizia txikia bada, ebakidura sinplearen bidez tratatu daiteke; minbizia txikiagoa bada, Mohs-en kirurgia gomendatzen da oro har.
Baso-zelulen kartzinomak mundu osoko minbizi guztien %32a hartzen du gutxienez. Melanoma ez diren larruazaleko minbizietatik, %80 inguru zelula basaletako minbiziak dira. Estatu Batuetan, gizonezko zurien %35 inguru eta emakume zurien %25 inguru zelula baso-zelulen kartzinomak jasaten dituzte bizitzako uneren batean.
○ Diagnostikoa eta Tratamendua
#Dermoscopy
#Skin biopsy
#Mohs surgery